FLI1 and GATA1 govern transcription: new insights into FLI1-related platelet disorders.

Germline variants of FLI1, essential for megakaryopoiesis, are linked to bleeding disorders, platelet aggregation defects and mild thrombocytopenia. However, the mechanisms behind these abnormalities remain unclear. This study aims to elucidate the impact of FLI1 variants on human megakaryocytes and platelets.

A gain of function variant in RGS18 candidate for a familial mild bleeding syndrome.

Background: Inherited platelet diseases are bleeding disorders characterized by either defects in platelet count or platelet function, the latter being less common and very heterogeneous. Numerous gene variants associated with abnormal receptors, granules, and signaling pathways have been reported. Despite significant advancements in our understanding, many patients still lack a precise diagnosis.

Neural Disparity Refinement.

We propose a framework that combines traditional, hand-crafted algorithms and recent advances in deep learning to obtain high-quality, high-resolution disparity maps from stereo images. By casting the refinement process as a continuous feature sampling strategy, our neural disparity refinement network can estimate an enhanced disparity map at any output resolution. Our solution can process any disparity map produced by classical stereo algorithms, as well as those predicted by modern stereo networks or even different depth-from-images approaches, such as the COLMAP structure-from-motion pipeline.

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences.

Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the individualization of therapy in patients with comorbidities. To provide additional insight on the individualized approach to acromegaly management, six clinical cases of complex acromegaly treated with pasireotide-LAR for more than 5 years were reported.